Fulgent Genetics, Inc. Common Stock

Day range

$21.14 – $21.72

Open

$21.64

Prev close

$21.52

Volume

210.29K

Market cap

$592.13M

Shares out

27.52M

P/E

—

P/S

1.83

P/B

0.59

P/FCF

—

ROE

-8.4%

ROA

-7.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 28, 2026

• Investor presentationJul 30, 2026

  On July 30, 2026, the Company updated its investor presentation, which is available on the Investor Relations section of the Company's website at http://ir.fulgentgenetics.com.

• Clinical trial resultsMay 21, 2026

  the Company's full abstract entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020", presenting interim data from the Company's open-label, randomized Phase 2 study, was released.

• Annual meeting resultsMay 14, 2026

  On May 14, 2026 at 9:00 a.m. Pacific Time, the Company held its Annual Meeting... The following actions were taken at the Annual Meeting: Proposal 1 Election of the following nominees as directors of the Company... Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm... Proposal 3 Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. Proposal 4 Approval of the Company's 2026 Equity Incentive Plan.

• Investor presentationMay 1, 2026

  On May 1, 2026, the Company updated its investor presentation, which is available on the Investor Relations section of the Company's website at http://ir.fulgentgenetics.com.

• Lease agreementMar 17, 2026

  In connection with the APA Closing, the Buyer and Bakotic Pathology Associates entered into an Assignment and Assumption of Lease (the 'Lease Assignment'), dated March 17, 2026, pursuant to which Bakotic Pathology Associates assigned to the Buyer a Commercial Lease Agreement for approximately 29,099 square feet of laboratory and office space located at 6240 Shiloh Road, Alpharetta, GA 30005. The initial lease term commenced on August 1, 2015, and will terminate on July 31, 2032. The Lease provides for an annual base rent of $15.54 per square foot starting August 1, 2025, and increases by 2% each lease year.

Days to cover

7.4

Short interest

2.13M

Avg volume

287.79K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
  positiveZacks Investment Research· Sep 22, 2026
• Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Apr 17, 2026
• FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
  negativeGlobeNewswire Inc.· Mar 19, 2026
• Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031
  positiveGlobeNewswire Inc.· Jan 30, 2026
• Why Fulgent Genetics Stock Was Crushing It on Friday
  positiveThe Motley Fool· Aug 1, 2025